News

Opdualag is a fixed-dose dual immunotherapy combination treatment of the programmed death-1 (PD-1) inhibitor nivolumab and novel Lymphocyte activation gene-3 (LAG-3)-blocking antibody relatlimab. The drug is indicated to

The financing round has seen participation from existing investors Northpond Ventures, Leaps by Bayer, the impact investment unit of Bayer AG. New investors including the Myeloma Investment Fund,

Under the deal, the companies will develop radiolabelling chemistry and analytical methods which will be utilised in future pre-clinical and clinical studies. Actinium-225 (225Ac) is an alpha particle-emitting

Under the collaboration, funds managed by Blackstone Life Sciences (BXLS) will provide $329.1m (€300m) to speed up the pivotal studies as well as clinical development programme for a

The company’s application for the investigational, oral small molecule potassium-competitive acid blocker vonoprazan is based on the positive results announced earlier from its pivotal Phase III PHALCON-EE trial.

Incyte noted that the latest move comes after the acceptance and priority review of its sNDA for the cream in December last year. The FDA has extended the

An advanced PARP inhibitor, Lynparza is the first targeted treatment which is being developed by the companies to exploit DNA damage response (DDR) pathway deficiencies to kill cancer

Erasca’s ERAS-007 is currently being evaluated alone or in combination with different inhibitors to upstream MAPK pathway nodes as part of the MAPKlamp strategy. Under the collaboration, Lilly

An autologous TCR-T cell treatment, NTLA-5001 is intended to target the Wilms’ Tumor (WT1) antigen, which is highly expressed in AML and several other hematologic and solid tumours.